Jamy Ard
Overview
Explore the profile of Jamy Ard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1018
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trumbo P, Ard J, Bellisle F, Drewnowski A, Gilbert J, Kleinman R, et al.
Curr Dev Nutr
. 2025 Feb;
9(1):104516.
PMID: 39896730
Almonds are consumed by individuals around the world. Because almonds are rich in protein, unsaturated fatty acids, and fiber, a significant amount of research has been conducted on their role...
2.
Eggiman E, Feldman S, Ard J, Patel P
Dermatol Online J
. 2024 Dec;
30(5).
PMID: 39680963
Background: Acanthosis nigricans (AN) is a dermatologic skin condition that is often overlooked in its role as an indicator of underlying cardiovascular disorders. Recognizing the importance of AN beyond its...
3.
Ard J, Alexander L, Bessesen D, Burridge K, Hashmi S
Perm J
. 2024 Dec;
28(4):7-19.
PMID: 39654407
No abstract available.
4.
Sumithran P, Ard J
Lancet Diabetes Endocrinol
. 2024 Nov;
13(1):2-3.
PMID: 39608382
No abstract available.
5.
Edwards-Hampton S, Ard J
Diabetes Obes Metab
. 2024 Aug;
26 Suppl 4:28-38.
PMID: 39109480
Obesity is a complex chronic disease with increasing prevalence across the globe. Medical nutrition therapy (MNT) is an important component of obesity treatment, and low-calorie diets (LCDs) and very-low-calorie diets...
6.
Rubino D, Angelene H, Fabricatore A, Ard J
Obesity (Silver Spring)
. 2024 Jun;
32(7):1268-1280.
PMID: 38932728
Objective: The objective of this study was to evaluate the efficacy and safety of semaglutide 2.4 mg, a glucagon-like peptide-1 receptor agonist, by race and ethnicity, across three phase 3...
7.
Gudzune K, Kaplan L, Kahan S, Kumar R, Dunn J, Ahmad N, et al.
Endocr Pract
. 2024 Jun;
30(10):917-926.
PMID: 38901731
Objective: Limited recent evidence exists regarding weight-reduction preferences among people with obesity in the United States (US). We assessed preferred magnitudes of weight reduction among adults with obesity and how...
8.
Wadden T, Chao A, Machineni S, Kushner R, Ard J, Srivastava G, et al.
Nat Med
. 2024 Feb;
30(6):1784.
PMID: 38409593
No abstract available.
9.
Wadden T, Chao A, Machineni S, Kushner R, Ard J, Srivastava G, et al.
Nat Med
. 2023 Oct;
29(11):2909-2918.
PMID: 37840095
The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle intervention are unknown. This double-blind, placebo-controlled trial randomized (1:1) adults...
10.
Schumacher L, Ard J, Sarwer D
Front Public Health
. 2023 Jul;
11:1205880.
PMID: 37521999
Introduction: In June 2013, the American Medical Association (AMA), one of the most influential healthcare organizations in the United States, voted to recognize obesity as a disease. Many who supported...